탱고 테라퓨틱스(TNGX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $25.60 (-0.19%), 시가총액 $3.25B, 52주 범위 $1.28 ~ $27.77.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017
탱고 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
탱고 테라퓨틱스의 현재 주가는 $25.60 (-0.19%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
탱고 테라퓨틱스의 시가총액은 약 $3.25B입니다.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosi